Developing novel antimicrobial macrocycles against multidrug resistant bacteria that cause chronic lung infections
Developing novel antimicrobial macrocycles against multidrug resistant bacteria that cause chronic lung infections
批准号:
2750362
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Pseudomonas aeruginosa (Pa) is a ubiquitous opportunistic pathogen, classified by WHO as a priority one pathogen, for which the development of new therapeutics is critical. Pa is responsible for 10-20% of nosocomial infections and possesses a suite of therapeutic resistance mechanisms. Many Pa resistance mechanisms are intrinsic; however, Pa readily acquires and utilises further mechanisms via adaptive traits, and the acquisition of new genetic material. Antimicrobial resistant Pa is a major cause of morbidity and mortality in cystic fibrosis (CF) patients (~10,000 in the UK and ~100,000 worldwide) and people with non-CF bronchiectasis (50,000-300,000 in the UK alone). Once they have colonised the CF lung, Pa isolates can establish a multidrug resistant infection, rapidly reducing treatment options. These multidrug resistant infections become impossible to eradicate, leading to dramatic loss of lung function. Previously, a divergent commercial macrocycle compound library was screened against clinical strains of multidrug resistant Pa. Novel hits were generated; these were either resistance-breakers which potentiated existing antibiotics, or direct-acting antimicrobials which inhibited resistant Pa. A cheminformatics approach was used to cluster and prioritise the compounds, and chemical synthetic routes for resynthesis and derivation of the prioritised compounds were then established. The research will encompass investigations of the mechanisms of the prioritised hits against resistant Pa using a combination of microbiological, genomic, and chemical proteomics approaches. The prioritised hits will be profiled against known resistant Pa strains to evidence any cross-resistance with known antibiotics or potentiators. Whole genome sequencing will be used to establish and identify mutations conferring resistance in known resistant isolates relative to baseline strains. For the chemical proteomics approach, photoreactive chemical probes mimicking structures and biological activities of the selected hits will be used to tag and enrich protein targets of interest. They will also be used to investigate the interactions between the chemical probes and potential targets at the molecular level. This interdisciplinary project intends to address a public health issue at the interfaces between medicinal chemistry, chemical biology, microbiology, and chem/bioinformatics. The overall aim is to further both antimicrobial resistance research and antibiotic discovery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
Novel-miR-1134调控LHCGR的表达介导拟
穴青蟹卵巢发育的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:崔文晓
-
依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
-
批准号:82304677
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:边兴博
-
依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
-
批准号:82304658
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘亚
-
依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
-
批准号:32102747
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李婉雁
-
依托单位:
novel_circ_001042/miR-298-5p/Capn1轴调节线粒体能量代谢在先天性肛门直肠畸形发生中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:唐晓冰
-
依托单位:
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:张瑜
-
依托单位:
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
-
批准号:82070530
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:白玉作
-
依托单位:
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
-
批准号:32002421
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:修云吉
-
依托单位:
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
-
批准号:82072775
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:薛皓
-
依托单位:
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
-
批准号:31902347
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2019
-
负责人:闫红伟
-
依托单位: